Nedaplatin(Synonyms: NSC 375101D)


Nedaplatin (Synonyms: NSC 375101D) 纯度: ≥98.0%

Nedaplatin (NSC 375101D) 是顺铂衍生物和DNA损伤剂。

Nedaplatin(Synonyms: NSC 375101D)

Nedaplatin Chemical Structure

CAS No. : 95734-82-0

规格 价格 是否有货 数量
10 mg ¥810 In-stock
50 mg ¥3096 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Nedaplatin 相关产品


  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus


Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.

(In Vitro)

Nedaplatin (NSC 375101D, NDP) is a derivative of cisplatin which produced less nausea & vomiting and nephrotoxicity. the effect of NDP on the 7-ethyl-1-hydroxy-CPT (the active form of CPT-11)-induced inhibitory effect on DNA topoisomerase I was examined. The topoisomerase I-inhibitory effect of 7-ethyl-1-hydroxy-CPT was enhanced 10-fold in the presence of Nedaplatin (NSC 375101D, NDP) at microgram/milliliter concentrations[1]. Nedaplatin (NSC 375101D, NDP) was developed as a second generation platinum complex. Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP). At the high-dose of Nedaplatin (NSC 375101D, NDP) in FN therapy, a reduction of tumour size and long-term tumour-free survival were frequently observed. The survival effect of the combinations of Nedaplatin (NSC 375101D, NDP) with 5-FU was superior to those of the combination of CDDP with 5-FU. In conclusion, the sequence-dependent antitumour efficacy and toxicity of the combination of NDP or CDDP with 5-FU was demonstrated in this study, and FN therapy appeared to be the most efficient regimen as a clinical therapy[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial








Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
4°C 2 years


In Vitro: 

H2O : 13.6 mg/mL (44.86 mM; Need ultrasonic and warming; DMSO can inactivate Nedaplatin’s activity)

DMF : < 1 mg/mL (insoluble; DMSO can inactivate Nedaplatin’s activity)

浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.2984 mL 16.4919 mL 32.9837 mL
5 mM 0.6597 mL 3.2984 mL 6.5967 mL
10 mM 0.3298 mL 1.6492 mL 3.2984 mL



  • [1]. Kanzawa, F., et al., In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res, 2001. 7(1): p. 202-9.

    [2]. Uchida, N., et al., Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer, 1998. 34(11): p. 1796-801.